An analysis of FDA complete response letters does not reveal a big uptick – but the year is not over yet.
Welcome to the calm before the Covid-19 storm.
Curevac’s market cap has ballooned almost fivefold since floating, sending the mRNA company into the record books.
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.
Big pharma pipelines are getting smaller, but novel medicines are being tested in more indications than ever before, a new analysis finds.
The pandemic prompts only a slight drop in medtech approvals.
Medtechs going public in 2020 raised a decent amount of cash, but have had a turbulent time of it since.
Fortunately for medical device start-ups, it takes more than a pandemic to put venture capitalists off doing deals.
Second-quarter deal values plummeted as Covid-19 spread and the prices of target companies spiralled.